In this study, we successfully developed a magnetic nanocarrier of Vincristine based on the active targeting system of drug delivery using dual folic acid/transferrin ligand-containing PMNPs, namely, PMNP-VCR-FA-TF, the efficacy of which was tested on Y79 retinoblastoma cells. This evidence concerns the gene TF and retinoblastoma.